Lung cancer screening using low-dose CT scans in high-risk individuals
Official title: Lung Cancer Screening With Low-dose CT in China (CLUS Study) Version 3.0
Run by Shanghai Chest Hospital · NCT05494021 · Data updated 2026-11-12
This study is testing if low-dose CT scans can help find lung cancer earlier in people aged 45 to 75 who are at high risk.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 45 Years to 75 Years |
| Sex | All |
| Enrollment | 100000 (estimated) |
| Sponsor | Shanghai Chest Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | January 1, 2022 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | August 9, 2022 |
| Trial ID | NCT05494021 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 45-75 with a history of significant smoking, family history of cancer, or exposure to carcinogens.
✕Probably not a fit
Patients who have had a chest CT scan in the past 12 months or a history of any cancer within the last 5 years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of various lung cancer screening strategies, specifically focusing on low-dose computed tomography (LDCT) in high-risk individuals aged 45-75. It aims to validate previous findings that showed a significant increase in early-stage lung cancer detection through LDCT compared to usual care. The study involves recruiting 100,000 participants who will undergo baseline and two biennial LDCT screenings, with follow-up assessments for lung cancer incidence and mortality. Additionally, blood samples will be collected for future research purposes.
Why it matters
Potential benefit: If successful, this study could significantly improve early detection of lung cancer, leading to better patient outcomes and reduced mortality rates.
How similar studies have gone: Previous versions of this study have shown success in increasing early-stage lung cancer detection rates, indicating a promising approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Eligible participants were those aged 45-75 years, and with either of the following risk factors: 1. history of cigarette smoking ≥ 20 pack-years, and, if former smokers, had quit within the previous 15 years; 2. malignant tumors history in immediate family members; 3. personal cancer history; 4. professional exposure to carcinogens; 5. long term exposure to second-hand smoke; 6. long term exposure to cooking oil fumes. Exclusion Criteria: * Had a CT scan of chest within last 12 months * History of any cancer within 5 years
Where it's running
-
Shanghai Chest hospital
Shanghai, Shanghai Municipality, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
ePRO in advanced lung cancer: emotional distress, brain metastasis, and symptom burden
This study tests how patients with advanced lung cancer—some with brain metastases—report emotional distress and symptoms over time using electronic questionnaires.
-
Urine VOC Test to Detect Lung Cancer in Never Smokers
A urine test that looks for volatile compounds is tested to see if it can help detect lung cancer in adults who have never smoked.
-
SI-B036 safety test in advanced and metastatic solid tumors
This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.
-
Guaraná Supplement for Cancer-Related Fatigue in People Undergoing Treatment
This study tests whether taking guaraná capsules helps reduce cancer-related fatigue and improve quality of life in adults with breast, lung, colorectal, or gastric cancer who are actively receiving treatment.
-
ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients
This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.
-
Olive oil before lung cancer surgery to see if it lowers chylothorax
This study tests whether drinking 40 mL of extra-virgin olive oil a few hours before lung cancer surgery can reduce chylothorax after tumor removal.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.